Is INMD a good stock to buy right now?

Based on our 6-factor quantitative model, InMode Ltd. (INMD) receives a "Hold" rating with a composite score of 46.9/100. It is ranked #1,450 out of 4,446 stocks. Key factor scores: Quality 43/100, Value 94/100, Momentum 29/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for INMD?

InMode Ltd. (INMD) has a "Hold" rating and 3-star score. The composite score of 46.9 ranks it #1,450 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is INMD in?

InMode Ltd. operates in the Healthcare sector (Medical Equipment industry) with a market cap of $868 million. It is classified as a small-cap stock.

Does INMD pay a dividend?

INMD does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is INMD's P/E ratio?

INMD has a trailing P/E ratio of 5.98x. The Healthcare sector average is 23.6x. This below-average P/E may indicate the stock is undervalued.

How profitable is INMD?

INMD's quality factor score is 43/100. Gross margin: 80.3%. ROE: 103.0% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is INMD valued compared to peers?

INMD's value factor score is 94/100 (higher = cheaper). Key multiples: P/E 6.0x, EV/EBITDA 1.6x. The stock appears attractively valued versus peers.

What is INMD's debt level?

INMD's debt-to-equity ratio is 0%. Sector average: 32%. Low leverage suggests conservative financial management.

INMD has a beta of 1.39, meaning it amplifies market moves. Stability score: 58/100.

Does INMD have high short interest?

INMD's short interest factor score is 17/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

INMD Stock Analysis: Top Small-Cap Hold (Score 46.9/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
INMD	-1.17%	-1.89%	+1.96%	-7.90%	-4.04%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-1.10%	-5.49%	+1.62%	-7.54%	-33.57%	-	-	-
Alpha vs Sector	+0.18%	-2.23%	+5.77%	-3.06%	-13.25%	-	-	-

Metric	INMD	Benchmark
P/E Ratio	6.0x	-75%
EV/EBITDA	1.6x	-75%
Price / Book	1.2x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
INMD InMode Ltd.	47	43	94	29	6.0x	103.0%	80.3%	45.9%	-	0.0x	$868M

Key Ratio	TTM	2024	2023	2022	2021	2020	2019	2018
Gross Margin %	0.8%	0.8%	0.8%	0.8%	0.9%	0.9%	0.9%	0.8%
Operating Margin %	0.3%	0.3%	0.4%	0.4%	0.5%	0.4%	0.4%	0.2%
EBITDA Margin %	0.3%	0.3%	0.4%	0.4%	0.5%	0.4%	0.4%	0.2%
Net Margin %	0.5%	0.5%	0.4%	0.4%	0.5%	0.4%	0.4%	0.2%
FCF Margin %	33.4%	33.4%	35.8%	39.6%	48.6%	38.2%	39.3%	36.4%
ROE %	1.0%	0.3%	0.3%	0.3%	0.4%	0.3%	0.3%	0.5%
ROA %	0.9%	0.2%	0.2%	0.3%	0.3%	0.3%	0.3%	0.3%
ROIC %	16.2%	16.2%	24.0%	34.2%	38.1%	31.1%	35.9%	100.1%

Line Item	TTM	2024	2023	2022	2021	2020	2019	2018
	$395M	$395M	$492M	$454M	$358M	$206M	$156M	$100M
	$317M	$317M	$411M	$381M	$304M	$175M	$136M	$85M
Gross Margin	80.3%	80.3%	83.6%	83.8%	85.0%	85.0%	87.1%	85.0%
	—	$13M	$13M	$12M	$10M	$9M	$6M	$4M
Depreciation	—	$728K	$623K	$680K	$517K	$416K	$302K	$184K
	$113M	$113M	$196M	$198M	$167M	$73M	$60M	$23M
EBIT	$113M	$113M	$196M	$198M	$167M	$73M	$60M	$23M
EBITDA	$113M	$113M	$196M	$199M	$168M	$73M	$60M	$24M
Operating Margin	28.5%	28.5%	39.8%	43.5%	46.8%	35.3%	38.1%	23.4%
EBITDA Margin	28.7%	28.7%	39.9%	43.7%	47.0%	35.5%	38.3%	23.6%
	—	-$38M	$19M	$40M	$3M	$1M	$883K	$1M
	$181M	$181M	$198M	$162M	$165M	$75M	$61M	$22M
Net Margin	45.9%	45.9%	40.2%	35.6%	46.2%	36.4%	39.1%	22.3%
	$2.29	$2.29	$2.37	$1.96	$2.03	$1.04	$2.09	$0.82
Diluted EPS	$2.29	$2.29	$2.37	$1.96	$2.03	$1.04	$2.09	$0.82

InMode Ltd. (INMD) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does InMode Ltd. Do?

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel. InMode Ltd. (INMD) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Moshe Mizrahy and employs approximately 480 people. With a market capitalization of $868M, INMD is one of the notable companies in the Healthcare sector.

InMode Ltd. (INMD) Stock Rating — Hold (April 2026)

As of April 2026, InMode Ltd. receives a Hold rating with a composite score of 46.9/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.INMD ranks #1,450 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, InMode Ltd. ranks #122 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

INMD Stock Price and 52-Week Range

InMode Ltd. (INMD) currently trades at $13.53. The stock lost $0.16 (1.2%) in the most recent trading session. The 52-week high for INMD is $19.09, which means the stock is currently trading -29.1% from its annual peak. The 52-week low is $12.72, putting the stock 6.4% above its annual trough. Recent trading volume was 1.2M shares, reflecting moderate market activity.

Is INMD Overvalued or Undervalued? — Valuation Analysis

InMode Ltd. (INMD) carries a value factor score of 94/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 5.98x, compared to the Healthcare sector average of 23.63x — a discount of 75%. The price-to-book ratio stands at 1.23x, versus the sector average of 2.75x. The price-to-sales ratio is 0.55x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, INMD trades at 1.57x EV/EBITDA, versus 6.34x for the sector.

Based on these multiples, InMode Ltd. appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.

InMode Ltd. Profitability — ROE, Margins, and Quality Score

InMode Ltd. (INMD) earns a quality factor score of 43/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 103.0%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 92.3% versus the sector average of -33.1%.

On a margin basis, InMode Ltd. reports gross margins of 80.3%, compared to 71.5% for the sector. The operating margin is 28.5% (sector: -66.1%). Net profit margin stands at 45.9%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

INMD Debt, Balance Sheet, and Financial Health

InMode Ltd. has a debt-to-equity ratio of 0.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $0. Cash and equivalents stand at $155M.

INMD has a beta of 1.39, meaning it is more volatile than the broader market — a $10,000 investment in INMD would be expected to move 39.1% more than the S&P 500 on any given day. The stability factor score for InMode Ltd. is 58/100, reflecting average volatility within the normal range for its sector.

InMode Ltd. Revenue and Earnings History — Quarterly Trend

In TTM 2026, InMode Ltd. reported revenue of $395M and earnings per share (EPS) of $2.29. Net income for the quarter was $181M. Gross margin was 80.3%. Operating income came in at $113M.

In FY 2024, InMode Ltd. reported revenue of $395M and earnings per share (EPS) of $2.29. Net income for the quarter was $181M. Gross margin was 80.3%. Revenue grew -19.8% year-over-year compared to FY 2023. Operating income came in at $113M.

In FY 2023, InMode Ltd. reported revenue of $492M and earnings per share (EPS) of $2.37. Net income for the quarter was $198M. Gross margin was 83.6%. Revenue grew 8.3% year-over-year compared to FY 2022. Operating income came in at $196M.

In FY 2022, InMode Ltd. reported revenue of $454M and earnings per share (EPS) of $1.96. Net income for the quarter was $162M. Gross margin was 83.8%. Revenue grew 27.0% year-over-year compared to FY 2021. Operating income came in at $198M.

Over the past 8 quarters, InMode Ltd. has demonstrated a growth trajectory, with revenue expanding from $100M to $395M. Investors analyzing INMD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

INMD Dividend Yield and Income Analysis

InMode Ltd. (INMD) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

INMD Momentum and Technical Analysis Profile

InMode Ltd. (INMD) has a momentum factor score of 29/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 52/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 17/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

INMD vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, InMode Ltd. (INMD) ranks #122 out of 838 stocks based on the Blank Capital composite score. This places INMD in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing INMD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full INMD vs S&P 500 (SPY) comparison to assess how InMode Ltd. stacks up against the broader market across all factor dimensions.

INMD Next Earnings Date

No upcoming earnings date has been announced for InMode Ltd. (INMD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy INMD? — Investment Thesis Summary

InMode Ltd. presents a balanced picture with arguments on both sides. The value score of 94/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 29/100, a headwind for near-term performance.

In summary, InMode Ltd. (INMD) earns a Hold rating with a composite score of 46.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on INMD stock.

Related Resources for INMD Investors

Explore more research and tools: INMD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare INMD head-to-head with peers: INMD vs AZN, INMD vs SLGL, INMD vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

InMode to Present at the 25th Annual Needham Virtual Healthcare Conference

InMode CFO Sees Demand Stabilizing, Targets Flat 2026 Revenue as North America Rebuild Begins

InMode Shares Rise after Board Launches New Buyback Program

InMode (INMD) Valuation Check As New US$ Share Buyback Targets Around 10% Of Outstanding Stock

InMode Board Approves Buyback Covering Nearly 10% Of Stock

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks